Annual Press Conference 2011 - Boehringer Ingelheim

More documents

Recommendations

Info

Key Messages 2011 Lead own R&D to success Launch medications in: • Diabetes • Oncology • Hepatitis C • Idiopathic Pulmonary Fibrosis Build and expand new therapeutic areas • Position PRADAXA® on the market • Launch Linagliptin in diabetes • Build Oncology and Hepatitis C Annual Press Conference 2011 Implement strategy • Strategy of organic growth • Expand Biopharmaceuticals, process development, production of biological active ingredients • Expand Animal Health, focus on vaccines • Continous increase of investments in R&D Begin of a new growth phase • 2011 and beyond • Solid mid-range single digit growth projection • Increase of profitability expected • Secure sustainable independence 36
Annual Press Conference 2011 Business Year 2010
Page 1 and 2: Annual Press Conference 2011 Busine
Page 3 and 4: Highlights of the business year 201
Page 5 and 6: PRADAXA® for Stroke Prevention in
Page 7 and 8: Our Businesses Net sales maintained
Page 9 and 10: Key Messages 2010 125 years more he
Page 11 and 12: Challenges of 2010 well managed Con
Page 13 and 14: Prescription Medicines Strong core
Page 15 and 16: Consumer Health Care Continued grow
Page 17 and 18: Top 10 Global Corporations 2010 in
Page 19 and 20: Animal Health Strong growth of 5 co
Page 21 and 22: Industrial Customer Business (ICB)
Page 23 and 24: Dynamic growth in emerging markets
Page 25 and 26: Operating Cash Flow covers investin
Page 27 and 28: The basis of longterm independence
Page 29 and 30: Outlook 2011 Andreas Barner Chairma
Page 31 and 32: Diabetes: Alliance with Eli Lilly a
Page 33 and 34: Biopharmaceuticals: Our Sites Cell
Page 35: Innovative power of our employees a

Annual Press Conference 2011 - Boehringer Ingelheim

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?